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Summary
Background: Triple negative breast cancer (TNBC) is char-
acterized by aggressive clinical course and is unresponsive
to anti-HER2 and endocrine therapy. TNBC is difficult to
treat and is often lethal. Given the need to find new targets
for therapy we explored clinicopathological significance of
copy number gain of FGFR1 and c-MYC. Our aim was to
determine the impact of FGFR1 and c-MYC copy number
gain on clinical course and outcome of TNBC.
Methods: FGFR1 and c-MYC gene copy number alter-
ations were evaluated in 78 archive TNBC samples using
TaqMan based quantitative real time PCR assays.
Results: 50% of samples had increased c-MYC copy num-
ber. c-MYC copy number gain was associated with TNBC in
contrast to ER positive cancers. Our results showed signifi-
cant correlation between c-MYC copy number gain and
high grade of TNBCs. This suggests that c-MYC copy num-
ber could be an useful prognostic marker for TNBC
patients. c-MYC copy number gain was associated with
high pTNM stage as well as lobular and medullary tumor
subtypes. 43% of samples had increased FGFR1 copy
number. No correlations between FGFR1 copy number
gain and clinicopathological variables were observed.
Conclusions: We identified c-MYC copy number gain as a
prognostic marker for TNBC. Our results indicate that c-
Kratak sadr`aj
Uvod: Trostruko negativne karcinome dojke karakteri{e agre -
 sivan klini~ki tok i neosetljivost na endokrinu i anti-HER2
tera piju. Ovi tumori se te{ko le~e i ~esto su letalni. Zbog
potrebe za novim tipovima terapije, ispitali smo klini~ko-pa -
tolo{ki zna~aj pove}anja broja kopija FGFR1 i c-MYC onko -
ge na. Cilj rada je bio da se utvrdi uticaj pove }anja broja
kopija FGFR1 i c-MYC na klini~ki tok i ishod trostruko ne -
gativnog karcinome dojke.
Metode: Promene u broju kopija FGFR1 i c-MYC gena odre -
 |ene su kvantitivnim PCR-om u realnom vremenu kod 78
arhivskih uzoraka trostruko negativnog karcinome dojke.
Rezultati: 50% ispitanih uzoraka je imalo pove}an broj
kopija c-MYC. Pove}anje broja kopija c-MYC gena je aso -
cirano sa trostruko negativnim karcinomima dojke u pore -
|enju sa ER pozitivnim karcinomima. Amplifikacija c-MYC
je asocirana sa visokim gradusom trostruko negativnih
karcinoma. Iz ovog rezultata proizilazi da bi se broj kopija
c-MYC mogao smatrati korisnim prognosti~kim markerom
za TNBC pacijente. Pove}anje broja kopija c-MYC gena je
asocirano i sa visokim stadijumom tumora kao i sa lobu -
larnim i medularnim podtipom. 43% ispitanih uzoraka je
imalo pove}an broj kopija FGFR1. Nisu utvr|ene nikakve
korelacije izme|u pove}anja broja kopija FGFR1 i klini~kih
i histopatolo{kih parametara tumora.
List of abbreviations: CISH, chromogenic in situ hybridization;
c-MYC; CNA, copy number alterations; DFI, disease free interva;
ER, estrogen receptor; FFPE, formalin-fixed, paraffin-embedded;
FGFR1, fibroblast growth factor receptor 1; IHC, immunohisto-
chemistry; HER2, human epidermal growth factor receptor 2;
OS, overall survival; PR, progesterone receptor; qPCR, quantita-
tive real time PCR; TNBC, triple negative breast cancer 
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Introduction
Triple negative breast cancer (TNBC) is defined
by the lack of expression of estrogen (ER), proges-
terone (PR) and human epidermal growth factor
receptor 2 (HER2). It accounts for 10 to 20% of all
invasive breast cancer cases (1). TNBC is a highly het-
erogeneous disease and is usually an invasive ductal
carcinoma of no special type with a high histological
grade and mitotic index (1). It is characterized by poor
prognosis and aggressive clinical course (2–4).
Currently the only systemic therapy available for
TNBC is conventional cytotoxic chemotherapy but it’s
effects seem to be insufficient (5, 6). Identifying
molecular targets and devising new therapeutics for
these targets is an ongoing effort and imperative for
the development of a successful therapy for TNBC. 
Fibroblast growth factor receptor 1 (FGFR1)
belongs to the fibroblast growth factor receptor family
of transmembrane receptor tyrosine kinases. It has an
important role in many cellular processes such as cell
differentiation, proliferation, migration and apoptosis
(7). Aberrant FGFR signaling has been associated with
cancerogenesis in several human cancers thus making
it a potential therapeutic target (7). Gene amplification
is one of the most commonly identified FGFR1 aber-
rations in breast cancer. FGFR1 amplification was
shown to be associated with invasive breast cancer
suggesting it could influence breast cancer progres-
sion by contributing to the invasive transition processes
(8). While FGFR1 amplification was associated with
poor prognosis in ER positive breast cancer (9), its role
in TNBC is far less clear. To date there have been only
a few reports of FGFR1 alternations and their impact
on TNBC progression and prognosis.
c-MYC protein is a transcription factor that
serves as a key regulator of most aspects of cellular
function including metabolism, replication, growth,
differentiation and cell death (10). c-MYC over -
expression and gene amplification have been detect-
ed in a majority of human cancers including breast
cancer. c-MYC expression and signaling were found
to be elevated in TNBCs compared to hormone re -
ceptor positive cancers and linked to poor prognosis
(11). c-MYC amplification was shown to be preferen-
tially associated with invasive zones of breast cancer
(12) and several studies have indicated that c-MYC
may play an important role in aggressive breast can-
cers with poor prognosis (13, 14). 
The main goals of this study were to evaluate
the rates and prognostic significance of FGFR1 and c-
MYC copy number alterations (CNA) in TNBC.
Materials and Methods
Samples
Seventy eight breast carcinoma samples ob -
tained from the Institute for Oncology and Radiology
of Serbia that were confirmed negative for ER, PR
and HER-2 were included in this study. ER, PR and
HER-2 expression were evaluated using commercial
semi quantitative immunohistochemistry (IHC) assays,
Dako, according to the manufacturer recommended
procedure. The scoring system included the percent-
age of stained cells on a score from 0 to 5, and the
intensity of their staining on a score from 0 to 3.
Cases with the overall IHC score <4 were considered
negative for ER and PR expression (15). An overall
score of 0 or 1+ for IHC staining of HER2 expression
was regarded as negative. Score of 2+ was consid-
ered equivocal and for these cases HER2 negative
status was confirmed by chromogenic in situ
hybridization (CISH) (16).
All tumor samples and their corresponding nor-
mal tissue were formalin-fixed, paraffin-embedded
(FFPE). All relevant histopathologic and clinical
parameters (age, tumor type, pN stage, pT stage,
pTNM stage, Nottingham combined histologic grade,
disease free survival, overall survival) were retrieved
from patient’s medical records.
This study was approved by the Institute for
Oncology and Radiology of Serbia ethics committee
number 4321-01 and carried out in accordance with
the ethical standards laid down in the 1964 Decla -
ration of Helsinki, the International Ethical Guidelines
for Biomedical Research Involving Human Subjects
(CIOMS), Geneva 1993, and the Guidelines for Good
Clinical Practice CPMP/ICH/135/95), September
1997.
MYC may contribute to TNBC progression. We observed
no significant association between c-MYC and/or FGFR1
copy number status and patient survival. 
Keywords: c-MYC; copy number gain; FGFR1; triple
negative breast cancer
Zaklju~ak: Utvrdili smo da je pove}anje broja kopija c-MYC
prognosti~ki marker za trostruko negativne karcinome dojke.
Na{i rezultati pokazuju da c-MYC mo`e da doprinese pro -
gresiji trostruko negativnih tumora. Nije opa`ena statisti~ki
zna~ajna asocijacija izme|u broja kopija c-MYC i/ili FGFR1
onkogena i pre`ivljavanja pacijenata.
Klju~ne re~i: c-MYC; FGFR1; pove}anje broja kopija
gena; trostruko negativan karcinom dojke
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DNA extraction 
Genomic DNA was extracted from all samples
using Kapa Biosystems Express Extract Kit (KK7151,
Kapa Biosystems, Wilmington, MA, USA) according
to the manufacturers recommended protocol. The
quality of the extracted DNA was verified by agarose
gel electrophoresis. Concentrations and purity were
assessed spectrophotometrically using A260 / A280
absorbance ratios (NanoDrop Technologies, Wilming -
ton, DE, USA). Extracted and purified DNA was
stored at +4 °C until further analyses.
Copy number analysis by quantitative real time
PCR
Copy number analyses of FGFR1 and c-MYC
genes were done by quantitative real time PCR
(qPCR) using TaqMan based assays. c-MYC assay
included highly specific forward and reverse primers
as well as a 6-Fam-TAMRA labelled probe: F5’GGAC-
GACGAGACCTTCATCAA-3’, R5’-CCAGCTTCTCT-
GAGACGAGCTT-3’, TaqMan Probe 6-FAM-5’-
AGAAGCCGCTCCACATACAGTCCTGG-3‘-TAMRA.
FGFR1 gene copy number was evaluated using
Hs00237051_cn TaqMan assay (Applied Biosystems,
Foster City, CA, USA). RNase-P was used as a refer-
ence gene (4403326, Applied Biosystems). Cali -
bration was done using DNA isolated from normal
breast tissue.
Each sample was prepared in duplicate while
normal DNA controls were prepared in triplicate.
Total reaction volume was 15 mL. For c-MYC, reaction
contained primers/probe ratio of 3:1 (0.1 mmol/L
probe: 0.3 mmol/L primers), 1x TaqMan Master Mix
and 40 ng of DNA. For FGFR1 or RNase-P reaction
contained 1x TaqMan Master Mix, 1x TaqMan Copy
Number Assay for FGFR1 or RNase-P gene and 40
ng of DNA. Each reaction contained two normal DNA
controls that were used as calibrators. PCR reactions
were carried out in the ABI Prism 7500 Sequence
Detection System at 95 °C for 10 minutes, followed
by 40 cycles at 95 °C for 15 seconds, and 60 °C for
1 minute. A mean Ct value of each duplicate was
used for relative quantitation of gene copy number
according to the Livak (2-DDCT) method. Each run
included a no-template control. The obtained results
were analysed by RQ Study Add ON software for
7500 v 1.3 SDS instrument with a confidence level of
95% (p<0.05). 
FGFR1 and c-MYC copy number were classified
as gain if average copy number ratio estimate given
by qPCR was ≥ 2.0.
Statistical analysis
Data analysis was performed with GraphPad
Prism 5 software (GraphPad Software, Inc. CA). The
correlations between clinicopathologic parameters
and CNA of c-MYC and FGFR1 genes were analysed
using Fisher’s exact test or the Chi-square test,
depending on test conditions. Survival analyses were
performed using Kaplan & Meier product-limit
method and the log rank test was used to determine
the significance of the difference between survival
curves. Overall survival (OS) was calculated from the
day after surgery to the last follow-up examination or
death of the patient and disease free survival (DFS)
was defined as time from the day after surgery to first
locoregional recurrence, distant recurrence or con-
tralateral disease. Statistical differences were consid-
ered significant when p value was < 0.05. 
Results
Copy number alternations of c-MYC and FGFR1
oncogenes
We analyzed 78 TNBC samples out of which 34
had increased FGFR1 copy number (43%) and 39
(50%) had increased c-MYC copy number. Com -
paring this findings with our previous results on recep-
tor positive breast cancer samples (17) it is evident
that the triple negative cohort has a significantly high-
er incidence of copy number gain for c-MYC
(p<0.005). 
We then correlated copy number gain of exam-
ined genes with the clinicopathologic parameters of
TNBC (Table I). Copy number gain of c-MYC onco-
gene was significantly associated with high histologi-
cal grade (p=0.008) and high pTNM stage (Table I).
Patients with lobular breast cancer were represented
more in the group with increased c-MYC copy num-
ber (p=0.014) and c-MYC copy number gain group
tended to have a higher representation of medullary
breast cancers (p=0.06). Surprisingly, the group with
no FGFR1 copy number gain had a higher percent-
age of pTNM stage 4 tumors (Table I). FGFR1 copy
number gain was not associated with any other clini-
copathologic variable. Neither of the analyzed genes
had any significant influence on patient OS and DFS
(Figure 1). 
Next, we analysed whether there were co-alter-
ations between FGFR1 and c-MYC oncogenes. 24
(31%) of samples had increased both FGFR1 and c-
MYC copy number, 25 (32%) had copy number gain
of one gene and 29 (37%) had no copy number gain
for either gene. Simultaneous copy number gain of
both genes was significantly associated with high his-
tological grade (p=0.039) and pTNM stage III (Table
I). Patients with no copy number gain for either gene
had a higher proportion of pTNM stage I tumors
compared to other groups while patients with copy
number gain of one gene had higher proportion of
pTNM stage IV tumors (Table I). No correlation with
patient survival was obtained (data not shown). 
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Table I Clinicopathological correlation according to c-MYC and/or FGFR1 copy number alterations in TNBC.
Abbreviations: np, number of patients per group; * – tubular, mucinous and other rare carcinoma types
pA – statistical significance between ductal and lobular tumors; pB – statistical significance between ductal and medullary tumors;
pC – statistical significance between ductal and other tumors, pD – statistical significance between lobular and medullary tumors;
pE – statistical significance between lobular and other tumors; pF – statistical significance between medullary and other tumors
p1 – statistical significance between stages I and II; p2 – statistical significance between stages I and III; p3 – statistical significance
between stages I and IV, p4 – statistical significance between stages II and III; p5 – statistical significance between stages II and IV;
p6 – statistical significance between stages III and IV
Bold indicates statistically significant values, p < 0.05.
Parameters Total(np=78)
c-MYC
np (%)
FGFR1
np (%)
c-MYC and FGFR1
np (%)
Gain
(np=39) p value
Gain
(np=34) p value
Both gain
(np=24)
One gain
(np=25) p value
Tumor type
Ductal 46 (59) 18 (46) pA  0.014 18 (53) pA  1.000 11 (46) 14 (56) pA  0.220
Lobular 14 (18) 11 (28) pB 0.064 6 (18) pB 0.129 6 (25) 5 (20) pB 0.071
Medullary 14 (18) 10 (26) pC 0.283 9 (26) pC 1.000 7 (29) 5 (20) pC 0.438
Other* 4 (5) 0 (0) pD 1.000 1 (3) pD 0.449 0 (0) 1 (4) pD 0.871
pE 0.011 pE 1.000 pE 0.105
pF 0.023 pF 0.274 pF 0.044
Stage
I 10 (13) 1 (2) p1 0.031 3 (9) p1 0.292 1 (4) 2 (8) p1 0.106
II 38 (49) 19 (49) p2 0.002 20 (59) p2 0.198 14 (59) 11 (44) p2 0.021
III 11 (14) 9 (23) p3 0.044 7 (20) p3 0.665 7 (29) 2 (8) p3 0.204
IV 19 (24) 10 (26) p4 0.087 4 (12) p4 0.732 2 (8) 10 (40) p4 0.284
p5 1.000 p5 0.027 p5 0.079
p6 0.139 p6 0.046 p6 0.009
pT stage
T1 and T2 68 (87) 34 (87) 1.000 28 (82) 0.317 21 (87) 20 (80) 0.356
T3 and T4 10 (13) 5 (13) 6 (18) 3 (13) 5 (20)
Nodal status
Negative 32 (41) 20 (51) 1.000 21 (64) 0.116 14 (59) 12 (48) 0.708
Pozitive 46 (59) 19 (49) 13 (36) 10 (41) 13 (52)
Histologic grade
I and II 52 (67) 20 (51) 0.008 20 (59) 0.237 12 (50) 16 (64) 0.039
III 26 (33) 19 (49) 14 (41) 12 (50) 9 (36)
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Discussion
Gene copy number gain is an important mecha-
nism of oncogene activation in cancer however the
prognostic significance of FGFR1 CNA in TNBC
remains unclear. Our study showed that FGFR1 gene
copy number was increased in 43% of examined sam-
ples which is a higher frequency than previously re -
ported by Lee et al. (18). However, Lee et al. (18)
examined FGFR1 amplification in TNBC using fluores-
cence in situ hybridization (FISH). A recent study com-
pared qPCR with FISH for assessing gene copy num-
ber (19). qPCR exhibited excellent correlation with
FISH at detecting copy number gain at 8 or more
copies. In the range from 2 to 6 copy number gain as
detected by qPCR, no copy number gains were found
using FISH. We would argue that qPCR is a more sen-
sitive method for detecting lower levels of copy number
gain. In our cohort the majority of samples with gene
amplification had a low-grade copy number in crease.
Therefore it is very likely that the higher frequency of
FGFR1 copy number gain detected in our study is due
to the higher sensitivity of qPCR. In the same study
Park et al. (19) demonstrated that FFPE tissue showed
lower levels of copy number gain compared to frozen
tissue therefore qPCR would be ideally suited for
assessing gene copy number gain in FFPE tissue. 
FGFR1 expression has impact on overall survival
in TNBC but its role in this disease is still controversial
(20). Literature data is scarce and offers conflicting
results. Cheng et al. (20) found that FGFR1 expression
in TNBCs was independently predictive for OS with
cases with high FGFR1 immunostaining having the
worst prognosis. Another study by Lee et al. (18)
showed no correlation between FGFR1 expression
and patient survival. The two studies differed in
immuno staining threshold used which highlights the
difficulty of comparing data from various studies.
Underlying mechanisms of FGFR1 overexpression in
TNBC are not well understood. While several studies
reported high level of correlation between FGFR1 pro-
tein overexpression and gene amplification, (21, 22),
a number of studies observed low protein expression
level in FGFR1 amplified tumors (23, 24). We found
no significant association between FGFR1 copy num-
ber gain and poor prognosis in TNBC or any of the
clinicopathologic parameters. Our results support the
notion that FGFR1 copy number status may not be an
informative independent prognostic factor for TNBC.
Figure 1 Kaplan–Meier survival curves. Impact of c-MYC and FGFR1 copy number on patient’s overall survival and disease free
survival. A c-MYC copy number gain had no influence on patient overall survival. B c-MYC copy number gain had no influence
on patient disease free survival. C FGFR1 copy number gain had no influence on patient overall survival. D FGFR1 copy number
gain had no influence on patient disease free survival
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c-MYC is frequently deregulated in breast can-
cer and is thought to contribute to breast cancer pro-
gression and poor prognosis. However, the detected
frequency of c-MYC amplification and its prognostic
significance have been inconsistent (25, 26) with the
reported frequency ranging from 1 to 94% (10). We
have detected c-MYC copy number gain in 50% of
TNBC samples, a frequency significantly higher than
in receptor positive breast cancers we previously
examined (17). Dillon et al. (27) detected that 75%
of TNBCs and 89% of basal-like tumors had c-MYC
amplification. However, this study analyzed only 20
TNBC samples. Here we have analyzed a much larger
cohort and demonstrated that c-MYC copy number
gain is a frequent event in TNBC. High frequency of
c-MYC overexpression and copy number gain
observed in TNBC, indicates that c-MYC deregulation
could be important for TNBC progression. 
We have found that c-MYC copy number gain
was associated with high grade TNBC. Determining
whether c-MYC copy number gain is present may
help identify patients with a greater risk of developing
high grade TNBC. Therefore, c-MYC could be consid-
ered as a prognostic marker of tumour progression. 
Copy number gain of c-MYC was significantly
associated with stage III of TNBC. These results are in
compliance with previous studies that found c-MYC
amplification to be associated with invasive zones of
breast cancer. These results further confirm that c-
MYC copy number gain could be a prognostic marker
of tumour progression in TNBC.
Our result that medullary tumors were associat-
ed with c-MYC copy number gain is consistent with a
previous study (28). This suggests that medullary
tumors have a distinct biology conductive to c-MYC
amplification. Our finding that lobular tumors were
associated with c-MYC copy number gain differs from
a study by Green et al. (29) which found c-MYC
expression to be more frequent in non-lobular
tumors. How ever, in the study by Green et al. (29)
only 15% of samples were TNBC. Our results support
the notion that triple negative lobular carcinoma is
genetically distinctive from non-triple negative lobular
carcinoma. Previous studies have shown that these
two types of lobular carcinoma differ in clinicopatho-
logic and IHC characteristics (30).
It has been shown that c-MYC overexpression is
associated with TNBC. Understanding the underlying
mechanisms of c-MYC expression may open new
approaches for therapy of TNBC. One study showed
that CDK inhibition effectively induced tumor regres-
sion in TNBC tumors that exhibit elevated c-MYC
expression (11). c-MYC could represent a promising
new target for TNBC therapy. 
We have found a high level of concordance
between FGFR1 and c-MYC copy number gain as 24
(31%) of samples had increased both FGFR1 and c-
MYC copy number. Simultaneous copy number gain
of both genes was associated with high grade and
high pTNM stage. However, this might be due to the
association of c-MYC gain with these parameters.
Simultaneous absence of copy number gain for both
genes was associated with pTNM stage I which fur-
ther supports the notion that CNA of these genes
occurs at a later phase of tumor progression. One
previous study identified frequent coamplification of
c-MYC and 8p11-p12 chromosomal region, where
FGFR1 is located, in invasive breast cancers (31).
Additionally, evidence exists that links c-MYC expres-
sion with more favorable response to FGFR inhibiting
therapy in lung cancers that exhibit FGFR1 amplifica-
tion (32). Therefore, examining FGFR1 and c-MYC
copy number and expression together may help
determine which patients would benefit the most
from FGFR inhibiting therapy. 
In conclusion, copy number gain of c-MYC is
associated with high grade and high stage TNBC as
well as lobular and medullary tumor subtypes. FGFR1
gene copy number has low prognostic implication for
TNBC. High level of concordance in c-MYC/FGFR1
copy number gain was detected in this cohort.
Simultaneous copy number gain of both genes was
significantly associated with high histological grade
and pTNM stage of TNBC. Though we found no sig-
nificant implications for patient outcome, a subset of
TNBC harbor copy number gain of c-MYC and
FGFR1 which could be of interest for TNBC therapy.
Patients with no copy number gain for either gene
had a higher proportion of pTNM stage I tumors con-
firming the predictive importance of these genes
amplification for tumor progression. 
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